Products

Date: 2017-07-20

Type of information: Granting of a patent

Product name: combination comprising an mRNA vaccine and an anti-PD-1 antibody

Compound: combination comprising an mRNA vaccine and an anti-PD-1 antibody

Therapeutic area: Cancer - Oncology - Infectious diseases

Action mechanism:

Company: Curevac (Germany)

Disease:

Latest news:

Patents:

• • On July 20, 2017, CureVac announced it has been granted a Notice of Allowance from the European Patent Office (EPO) for its patent application (EP 2958588) entitled, “Combination of Vaccination and Inhibition of the PD-1 Pathway.” The patent claims both composition of matter and methods of treatment for a vaccine/inhibitor combination comprising an mRNA vaccine and an anti-PD-1 antibody. Further, the patent covers a pharmaceutical composition and a kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases and infectious diseases.

Submission of marketing authorization application USA :

Submission of marketing authorization application UE:

Withdrawal of marketing authorization application USA:

Withdrawal of marketing authorization application UE:

US authorization:

UE authorization:

Favourable opinion UE:

Favourable opinion USA:

Orphan status USA:

Orphan status UE:

Pediatric exclusivit _USA:

Pediatric exclusivity UE:

OTC status:

Other news:

Is general: Yes